Japan is poised to buy more doses of the COVID-19 vaccine developed by Pfizer Inc. and BioNTech SE, a move that would pave the way for the country to immunize its adult population without using any of the shots it purchased from AstraZeneca PLC, which have been linked to rare blood clots.
Pfizer is expected to provide an additional 50 million doses by September in a contract that could be agreed on this month, government sources said Wednesday.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.